Skip to main content

Table 2 Comparisons of progression-free survival, time on treatment, and overall survival, between patients with multiple metastases versus single metastasis

From: Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US

Parameters

Progression-free survival

Time on treatment

Overall survival

HR

(95 % CI)

P-value 

HR

(95 % CI)

P-value

HR

(95 % CI)

P-value

Univariate analysis

 Multiple metastases (Ref: single metastasis)

1.98

(1.59,2.46)

<0.001*

1.78

(1.46, 2.18)

<0.001*

2.61

(1.78, 3.83)

<0.001*

Multivariable-adjusted analysisa

 Multiple metastases (Ref: single metastasis)

1.55

(1.21,1.98)

<0.001

1.33

(1.05, 1.67)

0.018*

1.77

(1.15, 2.74)

0.010*

 Age at index therapy initiation

0.98

(0.97,1.00)

0.043*

0.97

(0.95, 0.99)

<0.001*

1.01

(0.98, 1.04)

0.646

 Race (Ref: non-white)

  White

0.89

(0.71,1.12)

0.331

0.83

(0.67, 1.02)

0.074

0.88

(0.61, 1.29)

0.527

Insurance at mBC diagnosis (Ref: other or no insurance)

 Private

1.35

(0.85,2.14)

0.203

1.23

(0.81, 1.87)

0.326

1.12

(0.50, 2.50)

0.787

 Medicare only

1.47

(0.89,2.42)

0.128

1.46

(0.93, 2.31)

0.103

1.27

(0.53, 3.04)

0.584

Type of index treatment (Ref: endocrine therapyb)

 Chemotherapyc

1.18

(0.91,1.55)

0.216

2.29

(1.80, 2.90)

<0.001*

1.84

(1.20, 2.81)

0.005*

Line of index treatment (Ref: first-line)

 Second-line

1.49

(1.06,2.09)

0.023*

1.75

(1.27, 2.41)

0.001*

1.26

(0.69, 2.29)

0.448

 Third-line and above

1.34

(0.93,1.93)

0.114

1.18

(0.84, 1.65)

0.337

0.85

(0.44, 1.63)

0.618

mBC type (Ref: de novo)

 Recurrent with adjuvant endocrine therapy

1.27

(0.90,1.78)

0.175

1.53

(1.11, 2.12)

0.010*

1.40

(0.73, 2.64)

0.316

 Recurrent without adjuvant endocrine therapy

0.40

(0.25,0.66)

<0.001*

0.45

(0.29, 0.71)

0.001*

1.06

(0.49, 2.31)

0.882

 Adjusted CCI at index treatment initiation

1.08

(0.97,1.20)

0.155

1.09

(0.99, 1.21)

0.084

1.20

(1.02, 1.40)

0.024*

Bone metastasis at index therapy initiation

 (Ref: no bone metastasis)

1.56

(1.20,2.02)

0.001*

1.15

(0.91, 1.45)

0.233

0.85

(0.57, 1.27)

0.418

Performance status at index treatment initiation (Ref: ECOG 0)

 ECOG 1

1.44

(1.06,1.97)

0.021*

1.04

(0.79, 1.37)

0.785

1.76

(0.93, 3.32)

0.080

 ECOG 2 and 3

2.60

(1.70,3.98)

<0.001*

1.87

(1.26, 2.78)

0.002*

5.04

(2.45, 10.40)

<0.001*

 Unknown

1.77

(1.20,2.62)

0.004*

1.29

(0.90, 1.83)

0.166

3.15

(1.47, 6.72)

0.003*

Use of chemotherapy for mBC before index treatment initiation

0.82

(0.58,1.17)

0.283

0.89

(0.65, 1.23)

0.484

2.02

(1.15, 3.55)

0.014*

Duration from initiation of last adjuvant endocrine therapy to mBC diagnosis

1.00

(0.99,1.00)

0.374

1.00

(0.99, 1.00)

0.016*

1.00

(0.99, 1.01)

0.671

  1. BC breast cancer, CCI Charlson Comorbidity Index, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, mBC metastatic breast cancer, Ref reference
  2. * P < 0.05; Ref reference group
  3. aThe model adjusted for age, race, insurance type at mBC diagnosis, treatment type, line of the index treatment, mBC type, adjusted CCI, bone metastasis at index therapy initiation, ECOG performance status, prior chemotherapy for mBC, and months from the initiation of the last adjuvant endocrine therapy to mBC diagnosis
  4. bEndocrine therapy includes endocrine monotherapy, combination therapy with another endocrine agent, and everolimus-based therapies
  5. cChemotherapy includes chemotherapy monotherapy, combinational therapy of chemotherapy agents, and combinational therapy of chemotherapy and endocrine therapy
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us